Clinical Trial

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

Name: A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis — clinical trial record (NCT06649695)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab

Protocol Amendment History 1 change

critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-21

Trial Details

NCT Number	NCT06649695
Lead Sponsor	European Myeloma Network B.V. Collaborators: Janssen Research & Development, LLC
Conditions	AL Amyloidosis
Enrollment	30 participants
Start Date	2025-07-02
Primary Completion	2028-09 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-20